Pulmatrix board member Mark Iwicki resigns; Anand Varadan appointed

Pulmatrix, Inc.

Mark Iwicki resigned from board on July 23, 2021, with no disagreement over operations or policies.
Anand Varadan appointed to board as Class III director effective July 26, 2021.
Varadan brings commercialization expertise as CCO of Chiasma and former CCO of Karyopharm.
Appointment aligns with Pulmatrix's expansion into non-respiratory indications using iSPERSE technology.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Anand Varadan

Director

PULM · Pulmatrix, Inc.

Effective: 2021-07-26
Filed: July 27, 2021, 7:59 PM ET

On July 23, 2021, Anand Varadan was appointed to the board of directors of the Company, effective as of July 26, 2021, to serve as a Class III director

Departed

Mark Iwicki

Director

PULM · Pulmatrix, Inc.

Effective: 2021-07-23
Filed: July 27, 2021, 7:59 PM ET

On July 23, 2021, Mark Iwicki resigned from the board of directors of Pulmatrix, Inc. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anand Varadan was appointed as Director at Pulmatrix, Inc..

Action: appointed
Role: Director

Exact text from the filing

On July 23, 2021, Anand Varadan was appointed to the board of directors of the Company, effective as of July 26, 2021, to serve as a Class III director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Iwicki resigned as Director at Pulmatrix, Inc..

Action: resigned
Role: Director

Exact text from the filing

On July 23, 2021, Mark Iwicki resigned from the board of directors of Pulmatrix, Inc. (the “Company”).

View on SEC.gov

Pulmatrix, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-21-017825

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.